Oncotarget

Reviews:

Long noncoding RNAs in cutaneous melanoma: clinical perspectives

PDF  |  Full Text  |  How to cite

Oncotarget. 2017; 8:43470-43480. https://doi.org/10.18632/oncotarget.16478

Metrics: PDF 3082 views  |  Full Text 6512 views

Eva Hulstaert1, Lieve Brochez1, Pieter-Jan Volders2,3,4, Jo Vandesompele2,3,4 and Pieter Mestdagh2,3,4

1 Department of Dermatology, Ghent University Hospital, Ghent, Belgium

2 Center for Medical Genetics, Ghent University, Ghent, Belgium

3 Cancer Research Institute Ghent, Ghent University, Ghent, Belgium

4 Bioinformatics Institute Ghent, Ghent University, Ghent, Belgium

Correspondence to:

Eva Hulstaert, email:

Keywords: long non-coding RNA, melanoma, biomarkers, cancer therapy

Received: December 15, 2016 Accepted: March 13, 2017 Published: March 22, 2017

Abstract

Metastatic melanoma of the skin has a high mortality despite the recent introduction of targeted therapy and immunotherapy. Long non-coding RNAs (lncRNAs) are defined as transcripts of more than 200 nucleotides in length that lack protein-coding potential. There is growing evidence that lncRNAs play an important role in gene regulation, including oncogenesis. We present 13 lncRNA genes involved in the pathogenesis of cutaneous melanoma through a variety of pathways and molecular interactions. Some of these lncRNAs are possible biomarkers or therapeutic targets for malignant melanoma.